{"transactions":[{"id":4635941,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-10-06T20:05:06.000Z","date":"2026-10-02","kind":"sale","planned":false,"acquired":false,"shares":1864,"price":12.43,"value":23169.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":65022,"source":{"system":"sec-edgar","filing":"0001193125-26-415541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000119312526415541/ownership.xml","form_type":"4"}},{"id":677365,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-24T20:05:04.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":2785,"price":13,"value":36205.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026."}],"balance_after":1147064,"source":{"system":"sec-edgar","filing":"0001193125-26-363567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526363567/ownership.xml","form_type":"4"}},{"id":677364,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-24T20:05:04.000Z","date":"2026-08-20","kind":"sale","planned":true,"acquired":false,"shares":19890,"price":12.6,"value":250614.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price."}],"balance_after":1149849,"source":{"system":"sec-edgar","filing":"0001193125-26-363567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526363567/ownership.xml","form_type":"4"}},{"id":703503,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-24T21:26:12.000Z","date":"2026-07-22","kind":"sale","planned":false,"acquired":false,"shares":8111,"price":11.25,"value":91248.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price."}],"balance_after":148175,"source":{"system":"sec-edgar","filing":"0001193125-26-316279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526316279/ownership.xml","form_type":"4"}},{"id":715719,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:02:06.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":2641,"price":16.78,"value":44315.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price."}],"balance_after":66886,"source":{"system":"sec-edgar","filing":"0002019493-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000201949326000002/ownership.xml","form_type":"4"}},{"id":715208,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:06.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":4677,"price":18,"value":84186.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025."}],"balance_after":156286,"source":{"system":"sec-edgar","filing":"0001821530-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000182153026000002/ownership.xml","form_type":"4"}},{"id":743102,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:08:29.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001545794-26-000001","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000154579426000001/ownership.xml","form_type":"4"}},{"id":743101,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:08:29.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":35148,"source":{"system":"sec-edgar","filing":"0001545794-26-000001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000154579426000001/ownership.xml","form_type":"4"}},{"id":743098,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39286,"kind":"person","name":"Keresty Georgia","position":1,"cik":"0001773532","reported_name":"Keresty Georgia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:07:25.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001193125-26-266241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266241/ownership.xml","form_type":"4"}},{"id":743097,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39286,"kind":"person","name":"Keresty Georgia","position":1,"cik":"0001773532","reported_name":"Keresty Georgia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:07:25.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":41083,"source":{"system":"sec-edgar","filing":"0001193125-26-266241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266241/ownership.xml","form_type":"4"}},{"id":743228,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39684,"kind":"person","name":"GOODMAN JESSE","position":1,"cik":"0001756929","reported_name":"GOODMAN JESSE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:06:07.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001756929-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1756929/000175692926000002/ownership.xml","form_type":"4"}},{"id":743227,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39684,"kind":"person","name":"GOODMAN JESSE","position":1,"cik":"0001756929","reported_name":"GOODMAN JESSE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:06:07.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":33559,"source":{"system":"sec-edgar","filing":"0001756929-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756929/000175692926000002/ownership.xml","form_type":"4"}},{"id":743100,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:02:49.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001193125-26-266236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266236/ownership.xml","form_type":"4"}},{"id":743099,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:02:49.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":32609,"source":{"system":"sec-edgar","filing":"0001193125-26-266236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266236/ownership.xml","form_type":"4"}},{"id":743094,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:01:52.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001193125-26-266233","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266233/ownership.xml","form_type":"4"}},{"id":743093,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:01:52.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":216653,"source":{"system":"sec-edgar","filing":"0001193125-26-266233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266233/ownership.xml","form_type":"4"}},{"id":743096,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":11965,"kind":"person","name":"CHASE WILLIAM J","position":1,"cik":"0001563572","reported_name":"CHASE WILLIAM J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:00:39.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001563572-26-000001","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000156357226000001/ownership.xml","form_type":"4"}},{"id":743095,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":11965,"kind":"person","name":"CHASE WILLIAM J","position":1,"cik":"0001563572","reported_name":"CHASE WILLIAM J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:00:39.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":143893,"source":{"system":"sec-edgar","filing":"0001563572-26-000001","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000156357226000001/ownership.xml","form_type":"4"}},{"id":743091,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":2019,"kind":"person","name":"Bhanji Muna","position":1,"cik":"0001846905","reported_name":"Bhanji Muna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T22:57:33.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001193125-26-266230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266230/ownership.xml","form_type":"4"}},{"id":743090,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":2019,"kind":"person","name":"Bhanji Muna","position":1,"cik":"0001846905","reported_name":"Bhanji Muna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T22:57:33.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":36403,"source":{"system":"sec-edgar","filing":"0001193125-26-266230","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266230/ownership.xml","form_type":"4"}},{"id":867108,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T21:19:05.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":225400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":225400,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":225400},"source":{"system":"sec-edgar","filing":"0001193125-26-088269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088269/ownership.xml","form_type":"4"}},{"id":867107,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-03T21:19:05.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":156400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":1169739,"source":{"system":"sec-edgar","filing":"0001193125-26-088269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088269/ownership.xml","form_type":"4"}},{"id":867106,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T21:18:31.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":65829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":65829,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":65829},"source":{"system":"sec-edgar","filing":"0001193125-26-088260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088260/ownership.xml","form_type":"4"}},{"id":867105,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-03-03T21:18:31.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":1211,"price":13.78,"value":16687.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":156794,"source":{"system":"sec-edgar","filing":"0001193125-26-088260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088260/ownership.xml","form_type":"4"}},{"id":867104,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-03-03T21:18:31.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":46080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit"}],"balance_after":158005,"source":{"system":"sec-edgar","filing":"0001193125-26-088260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088260/ownership.xml","form_type":"4"}},{"id":867100,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T21:17:34.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":87543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":87543,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":87543},"source":{"system":"sec-edgar","filing":"0001193125-26-088254","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088254/ownership.xml","form_type":"4"}},{"id":867099,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:17:34.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":61280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":160963,"source":{"system":"sec-edgar","filing":"0001193125-26-088254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088254/ownership.xml","form_type":"4"}},{"id":867103,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T21:16:13.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":10505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":10505,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":10505},"source":{"system":"sec-edgar","filing":"0001193125-26-088241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088241/ownership.xml","form_type":"4"}},{"id":867102,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:16:13.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":607,"price":13.78,"value":8364.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":93864,"source":{"system":"sec-edgar","filing":"0001193125-26-088241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088241/ownership.xml","form_type":"4"}},{"id":867101,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:16:13.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":7353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":94471,"source":{"system":"sec-edgar","filing":"0001193125-26-088241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088241/ownership.xml","form_type":"4"}},{"id":868696,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:15:37.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":17250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":69527,"source":{"system":"sec-edgar","filing":"0001193125-26-088236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000119312526088236/ownership.xml","form_type":"4"}},{"id":867957,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T16:18:01.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":14204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":14204,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":14204},"source":{"system":"sec-edgar","filing":"0001193125-26-088258","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000119312526088258/ownership.xml","form_type":"4"}},{"id":867956,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T16:18:01.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":9943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":131192,"source":{"system":"sec-edgar","filing":"0001193125-26-088258","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000119312526088258/ownership.xml","form_type":"4"}},{"id":869003,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T16:17:09.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":56000,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001193125-26-088251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312526088251/ownership.xml","form_type":"4"}},{"id":869002,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-03T16:17:09.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":39200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":137733,"source":{"system":"sec-edgar","filing":"0001193125-26-088251","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312526088251/ownership.xml","form_type":"4"}},{"id":944472,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-07T21:05:54.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":34146,"price":9.21,"value":314484.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":1013339,"source":{"system":"sec-edgar","filing":"0001193125-26-006294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006294/ownership.xml","form_type":"4"}},{"id":944473,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-01-07T21:05:11.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":10397,"price":9.21,"value":95756.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":101528,"source":{"system":"sec-edgar","filing":"0001193125-26-006291","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006291/ownership.xml","form_type":"4"}},{"id":944470,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-07T21:05:06.000Z","date":"2026-01-05","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":9.35,"value":1402500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price."}],"balance_after":207453,"source":{"system":"sec-edgar","filing":"0001193125-26-006288","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006288/ownership.xml","form_type":"4"}},{"id":944471,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-07T21:03:52.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":9515,"price":9.21,"value":87633.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025."}],"balance_after":87118,"source":{"system":"sec-edgar","filing":"0001193125-26-006278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006278/ownership.xml","form_type":"4"}},{"id":944469,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T21:02:56.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":6379,"price":9.21,"value":58750.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":99683,"source":{"system":"sec-edgar","filing":"0001193125-26-006275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006275/ownership.xml","form_type":"4"}},{"id":944841,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-01-07T21:01:51.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":2989,"price":9.21,"value":27528.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":52277,"source":{"system":"sec-edgar","filing":"0001193125-26-006264","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000119312526006264/ownership.xml","form_type":"4"}},{"id":944918,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-07T16:05:16.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":8508,"price":9.21,"value":78358.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively."}],"balance_after":98533,"source":{"system":"sec-edgar","filing":"0001193125-26-006292","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312526006292/ownership.xml","form_type":"4"}},{"id":944597,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-07T16:04:38.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":11903,"price":9.21,"value":109626.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,022 and 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively."}],"balance_after":121249,"source":{"system":"sec-edgar","filing":"0001193125-26-006283","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000119312526006283/ownership.xml","form_type":"4"}},{"id":971169,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":false,"shares":8557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025."}],"balance_after":0,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":8557},"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971168,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":false,"shares":49959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025."}],"balance_after":8557,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":49959},"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971167,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":true,"shares":8557,"price":6.83,"value":58444.31,"ownership":{"direct":true},"balance_after":1047485,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971166,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":5355,"price":9.59,"value":51354.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price."}],"balance_after":1038928,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971165,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":32832,"price":9.47,"value":310919.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price."}],"balance_after":1044283,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971164,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":49959,"price":9.49,"value":474110.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price."}],"balance_after":1077115,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971163,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":true,"shares":49959,"price":6.83,"value":341219.97,"ownership":{"direct":true},"balance_after":1127074,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":1024945,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:13:00.000Z","date":"2025-10-01","kind":"sale","planned":false,"acquired":false,"shares":1871,"price":17.38,"value":32517.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":55266,"source":{"system":"sec-edgar","filing":"0001193125-25-230420","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000119312525230420/ownership.xml","form_type":"4"}},{"id":1025010,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-03T17:13:56.000Z","date":"2025-10-01","kind":"sale","planned":false,"acquired":false,"shares":31,"price":17.38,"value":538.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":105184,"source":{"system":"sec-edgar","filing":"0001193125-25-230424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000119312525230424/ownership.xml","form_type":"4"}},{"id":1057810,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":11965,"kind":"person","name":"CHASE WILLIAM J","position":1,"cik":"0001563572","reported_name":"CHASE WILLIAM J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T20:30:14.000Z","date":"2025-08-20","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":10.03,"value":1003000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on August 20, 2025 at each separate price."}],"balance_after":134693,"source":{"system":"sec-edgar","filing":"0000950170-25-110979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025110979/ownership.xml","form_type":"4"}},{"id":1081393,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-25T20:05:06.000Z","date":"2025-07-23","kind":"sale","planned":false,"acquired":false,"shares":7462,"price":14.02,"value":104617.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":106062,"source":{"system":"sec-edgar","filing":"0000950170-25-098774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025098774/ownership.xml","form_type":"4"}},{"id":1092346,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-07-03T20:11:49.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":1022,"price":9.82,"value":10036.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,022 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":95369,"source":{"system":"sec-edgar","filing":"0000950170-25-093852","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025093852/ownership.xml","form_type":"4"}},{"id":1092828,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-07-03T20:07:21.000Z","date":"2025-07-02","kind":"sale","planned":false,"acquired":false,"shares":2503,"price":9.95,"value":24904.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":57137,"source":{"system":"sec-edgar","filing":"0000950170-25-093844","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000095017025093844/ownership.xml","form_type":"4"}},{"id":1095303,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39684,"kind":"person","name":"GOODMAN JESSE","position":1,"cik":"0001756929","reported_name":"GOODMAN JESSE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T21:50:11.000Z","date":"2025-07-01","kind":"sale","planned":true,"acquired":false,"shares":1547,"price":9.23,"value":14278.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 3,094 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 31, 2025."}],"balance_after":24359,"source":{"system":"sec-edgar","filing":"0000950170-25-093302","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1756929/000095017025093302/ownership.xml","form_type":"4"}},{"id":1095302,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39684,"kind":"person","name":"GOODMAN JESSE","position":1,"cik":"0001756929","reported_name":"GOODMAN JESSE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T21:50:11.000Z","date":"2025-06-30","kind":"sale","planned":true,"acquired":false,"shares":1547,"price":9.56,"value":14789.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 3,094 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 31, 2025."}],"balance_after":25906,"source":{"system":"sec-edgar","filing":"0000950170-25-093302","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756929/000095017025093302/ownership.xml","form_type":"4"}},{"id":1106287,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39286,"kind":"person","name":"Keresty Georgia","position":1,"cik":"0001773532","reported_name":"Keresty Georgia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T20:07:28.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-087887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025087887/ownership.xml","form_type":"4"}},{"id":1106286,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39286,"kind":"person","name":"Keresty Georgia","position":1,"cik":"0001773532","reported_name":"Keresty Georgia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:07:28.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":31883,"source":{"system":"sec-edgar","filing":"0000950170-25-087887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025087887/ownership.xml","form_type":"4"}},{"id":1111611,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:36:09.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086287","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086287/ownership.xml","form_type":"4"}},{"id":1111610,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39664,"kind":"person","name":"Verwiel Frank","position":1,"cik":"0001545794","reported_name":"Verwiel Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:36:09.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":25948,"source":{"system":"sec-edgar","filing":"0000950170-25-086287","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086287/ownership.xml","form_type":"4"}},{"id":1111768,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39684,"kind":"person","name":"GOODMAN JESSE","position":1,"cik":"0001756929","reported_name":"GOODMAN JESSE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:33:07.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086277","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1756929/000095017025086277/ownership.xml","form_type":"4"}},{"id":1111767,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39684,"kind":"person","name":"GOODMAN JESSE","position":1,"cik":"0001756929","reported_name":"GOODMAN JESSE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:33:07.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":27453,"source":{"system":"sec-edgar","filing":"0000950170-25-086277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1756929/000095017025086277/ownership.xml","form_type":"4"}},{"id":1111609,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:30:38.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086271","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086271/ownership.xml","form_type":"4"}},{"id":1111608,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:30:38.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":23409,"source":{"system":"sec-edgar","filing":"0000950170-25-086271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086271/ownership.xml","form_type":"4"}},{"id":1111607,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":2019,"kind":"person","name":"Bhanji Muna","position":1,"cik":"0001846905","reported_name":"Bhanji Muna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:27:14.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to  11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086243/ownership.xml","form_type":"4"}},{"id":1111606,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":2019,"kind":"person","name":"Bhanji Muna","position":1,"cik":"0001846905","reported_name":"Bhanji Muna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:27:14.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":27203,"source":{"system":"sec-edgar","filing":"0000950170-25-086243","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086243/ownership.xml","form_type":"4"}},{"id":1111605,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":11965,"kind":"person","name":"CHASE WILLIAM J","position":1,"cik":"0001563572","reported_name":"CHASE WILLIAM J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:25:02.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086231/ownership.xml","form_type":"4"}},{"id":1111604,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":11965,"kind":"person","name":"CHASE WILLIAM J","position":1,"cik":"0001563572","reported_name":"CHASE WILLIAM J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:25:02.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":34693,"source":{"system":"sec-edgar","filing":"0000950170-25-086231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086231/ownership.xml","form_type":"4"}},{"id":1111603,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:23:03.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086223/ownership.xml","form_type":"4"}},{"id":1111602,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:23:03.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":57453,"source":{"system":"sec-edgar","filing":"0000950170-25-086223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086223/ownership.xml","form_type":"4"}},{"id":1162427,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":2019,"kind":"person","name":"Bhanji Muna","position":1,"cik":"0001846905","reported_name":"Bhanji Muna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-01T20:24:22.000Z","date":"2025-04-29","kind":"sale","planned":true,"acquired":false,"shares":265,"price":8.5,"value":2252.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 27, 2024."}],"balance_after":19203,"source":{"system":"sec-edgar","filing":"0000950170-25-061881","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025061881/ownership.xml","form_type":"4"}},{"id":1228401,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:43:16.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":45714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":45714,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":45714},"source":{"system":"sec-edgar","filing":"0000950170-25-032263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032263/ownership.xml","form_type":"4"}},{"id":1228400,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:43:16.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":679,"price":8.99,"value":6104.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":95369,"source":{"system":"sec-edgar","filing":"0000950170-25-032263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032263/ownership.xml","form_type":"4"}},{"id":1228399,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:43:16.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":96048,"source":{"system":"sec-edgar","filing":"0000950170-25-032263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032263/ownership.xml","form_type":"4"}},{"id":1228398,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:41:19.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":196000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":196000,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":196000},"source":{"system":"sec-edgar","filing":"0000950170-25-032248","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032248/ownership.xml","form_type":"4"}},{"id":1228397,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-04T21:41:19.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":136000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":1077115,"source":{"system":"sec-edgar","filing":"0000950170-25-032248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032248/ownership.xml","form_type":"4"}},{"id":1228396,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:34:03.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":67429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":67429,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":67429},"source":{"system":"sec-edgar","filing":"0000950170-25-032192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032192/ownership.xml","form_type":"4"}},{"id":1228395,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:34:03.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":47200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":113524,"source":{"system":"sec-edgar","filing":"0000950170-25-032192","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032192/ownership.xml","form_type":"4"}},{"id":1229973,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:28:45.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":59640,"source":{"system":"sec-edgar","filing":"0000950170-25-032141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000095017025032141/ownership.xml","form_type":"4"}},{"id":1228394,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:21:45.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":57143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":57143,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":57143},"source":{"system":"sec-edgar","filing":"0000950170-25-032086","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032086/ownership.xml","form_type":"4"}},{"id":1228393,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-03-04T21:21:45.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":2572,"price":8.99,"value":23122.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":111925,"source":{"system":"sec-edgar","filing":"0000950170-25-032086","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032086/ownership.xml","form_type":"4"}},{"id":1228392,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-03-04T21:21:45.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit"}],"balance_after":114497,"source":{"system":"sec-edgar","filing":"0000950170-25-032086","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032086/ownership.xml","form_type":"4"}},{"id":1229178,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T16:26:23.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":61714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":61714,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":61714},"source":{"system":"sec-edgar","filing":"0000950170-25-032125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025032125/ownership.xml","form_type":"4"}},{"id":1229177,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-04T16:26:23.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":43200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":130866,"source":{"system":"sec-edgar","filing":"0000950170-25-032125","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025032125/ownership.xml","form_type":"4"}},{"id":1230244,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T16:24:10.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":53714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":53714,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":53714},"source":{"system":"sec-edgar","filing":"0000950170-25-032101","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000095017025032101/ownership.xml","form_type":"4"}},{"id":1230243,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63443,"kind":"person","name":"Schultes Birgit C","position":1,"cik":"0002051419","reported_name":"Schultes Birgit C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-04T16:24:10.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":37600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":105215,"source":{"system":"sec-edgar","filing":"0000950170-25-032101","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051419/000095017025032101/ownership.xml","form_type":"4"}},{"id":1289484,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":2019,"kind":"person","name":"Bhanji Muna","position":1,"cik":"0001846905","reported_name":"Bhanji Muna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-31T21:17:16.000Z","date":"2025-01-29","kind":"sale","planned":true,"acquired":false,"shares":265,"price":9.97,"value":2642.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 27, 2024."}],"balance_after":19468,"source":{"system":"sec-edgar","filing":"0000950170-25-011757","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025011757/ownership.xml","form_type":"4"}},{"id":1308441,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":32222,"kind":"person","name":"Dube Michael P","position":1,"cik":"0002019493","reported_name":"Dube Michael P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:23:13.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":1372,"price":12.18,"value":16710.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":45640,"source":{"system":"sec-edgar","filing":"0000950170-25-003032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019493/000095017025003032/ownership.xml","form_type":"4"}},{"id":1308016,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63306,"kind":"person","name":"BASTA JAMES","position":1,"cik":"0001792726","reported_name":"BASTA JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-01-07T22:22:20.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":7074,"price":12.18,"value":86161.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":74497,"source":{"system":"sec-edgar","filing":"0000950170-25-003028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025003028/ownership.xml","form_type":"4"}},{"id":1308015,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":84337,"kind":"person","name":"Hicks Derek","position":1,"cik":"0001901282","reported_name":"Hicks Derek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:20:23.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":6502,"price":12.18,"value":79194.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1 and January 3, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":59878,"source":{"system":"sec-edgar","filing":"0000950170-25-003014","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025003014/ownership.xml","form_type":"4"}},{"id":1308014,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-07T22:19:54.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":26807,"price":12.18,"value":326509.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":941115,"source":{"system":"sec-edgar","filing":"0000950170-25-003012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025003012/ownership.xml","form_type":"4"}},{"id":1308170,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:16:22.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":8966,"price":12.18,"value":109205.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":77388,"source":{"system":"sec-edgar","filing":"0000950170-25-003002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017025003002/ownership.xml","form_type":"4"}},{"id":1308214,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T17:20:25.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":9557,"price":12.18,"value":116404.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":87666,"source":{"system":"sec-edgar","filing":"0000950170-25-003015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025003015/ownership.xml","form_type":"4"}},{"id":1310649,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:16:47.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":7422,"price":12.18,"value":90399.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":64048,"source":{"system":"sec-edgar","filing":"0000950170-25-002115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025002115/ownership.xml","form_type":"4"}},{"id":1310648,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:16:47.000Z","date":"2025-01-02","kind":"sale","planned":false,"acquired":false,"shares":556,"price":12.03,"value":6688.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 556 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":71470,"source":{"system":"sec-edgar","filing":"0000950170-25-002115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025002115/ownership.xml","form_type":"4"}},{"id":1315007,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-03T21:30:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":0,"derivative":{"exercise_date":"2025-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000950170-25-001232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017025001232/ownership.xml","form_type":"4"}},{"id":1315006,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T21:30:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 405 and 556 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024, respectively."}],"balance_after":86354,"source":{"system":"sec-edgar","filing":"0000950170-25-001232","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017025001232/ownership.xml","form_type":"4"}},{"id":1314725,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-03T21:30:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted  31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":0,"derivative":{"exercise_date":"2025-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0000950170-25-001236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025001236/ownership.xml","form_type":"4"}}],"next_cursor":"2025-01-03T21:30:05.000000Z,1314725"}